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Abstract
Background
Interventions based around objective measurement of adherence to antiretroviral drugs for
HIV have potential to improve adherence and to enable differentiation of care such that clini-
cal visits are reduced in those with high adherence. It would be useful to understand the
approximate upper limit of cost that could be considered for such interventions of a given
effectiveness in order to be cost effective. Such information can guide whether to implement
an intervention in the light of a trial showing a certain effectiveness and cost.
Methods
An individual-based model, calibrated to Zimbabwe, which incorporates effects of adher-
ence and resistance to antiretroviral therapy, was used to model the potential impact of
adherence monitoring-based interventions on viral suppression, death rates, disability
adjusted life years and costs. Potential component effects of the intervention were:
enhanced average adherence when on ART, reduced risk of ART discontinuation, and
reduced risk of resistance acquisition. We considered a situation in which viral load monitor-
ing is not available and one in which it is. In the former case, it was assumed that care would
be differentiated based on the adherence level, with fewer clinic visits in those demonstrated
to have high adherence. In the latter case, care was assumed to be primarily differentiated
according to viral load level. The maximum intervention cost required to be cost effective
was calculated based on a cost effectiveness threshold of $500 per DALY averted.
Findings
In the absence of viral load monitoring, an adherence monitoring-based intervention which
results in a durable 6% increase in the proportion of ART experienced people with viral
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load < 1000 cps/mL was cost effective if it cost up to $50 per person-year on ART, mainly
driven by the cost savings of differentiation of care. In the presence of viral load monitoring
availability, an intervention with a similar effect on viral load suppression was cost-effective
when costing $23-$32 per year, depending on whether the adherence intervention is used
to reduce the level of need for viral load measurement.
Conclusion
The cost thresholds identified suggest that there is clear scope for adherence monitoring-
based interventions to provide net population health gain, with potential cost-effective use in
situations where viral load monitoring is or is not available. Our results guide the implemen-
tation of future adherence monitoring interventions found in randomized trials to have health
benefit.
Introduction
Various potential means to improve adherence to antiretroviral therapy have been evaluated
in sub-Saharan Africa [1,2]. Most involve a component of counselling and/or support by clinic
staff or community based counsellors, which often takes place face-to-face but can also include
phone calls or text messaging. A key challenge with any such intervention is having access to a
reliable and objective indicator of the extent and pattern of the patient’s adherence. Objective
measures of adherence that do not rely on self-report are attractive in not being subject to
reporting bias and as such they have potential for routine use as a means of informing and tar-
geting interventions to improve adherence. Objective adherence measurement approaches
include recording of on-time drug pick-up and electronic monitors of adherence [3–7]. This
latter might consist of a device that enables clinic staff to read out the adherence history of the
patient since the last clinic visit [3,4], or perhaps even monitoring of adherence in real time
using mobile phone technology [3, 8, 9]. Real time monitoring means there is the potential to
react rapidly to missed doses to prevent default from care and reduce the risk of resistance
development. Adherence monitoring-based interventions could be used to enable differentia-
tion of care so that those with high adherence can have reduced visit frequency and/or attend
for pharmacy-only visits, allowing appreciable non-ART clinic cost savings, as has been pro-
posed based on viral load monitoring [10, 11]. In addition, even where viral load monitoring is
in place, adherence monitoring-based interventions have potential to replace viral load mea-
surement in people in whom viral suppression has been demonstrated.
Measured outcomes for studies of adherence monitoring-based interventions may include
percent of doses taken (often referred to in the drug adherence literature as execution), dura-
tion of treatment (persistence), frequency of ART interruption, and the proportion of people
with viral load suppression. However, the ultimate impact that adoption of such interventions
would have on key program outcomes such as death rates and disability-adjusted life years
(DALYs) averted is often unclear. Further, it is not intuitively clear how much money it is
worth spending on an adherence monitoring-based intervention in order for its introduction
to be cost-effective; i.e. of net health benefit given the opportunity costs of its introduction. In
thinking of designing such interventions it would be useful to understand the approximate
upper limit of cost that could be considered for an intervention of a given effectiveness, in
order for the intervention to be cost effective.
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In this paper we apply a model which captures the joint effects of adherence and viral resis-
tance on response to ART in order to provide a link between viral suppression outcomes and
these key program outcomes. This should facilitate use of data from trials of adherence moni-
toring-based interventions to be used to predict the population impact of the interventions,
and hence allow assessment of their cost effectiveness.
Methods
We used the HIV Synthesis model—an individual based model that models HIV sexual trans-
mission, progression and the effect of ART in adults that models ART effects through adher-
ence, accounting for current resistance to the ART regimen [11–14]. Variables simulated
include the current average adherence (a 3 month average, but see below) for those on ART,
viral load and CD4 count. Details of the assumptions in modelling of adherence are presented
in section 6 of S1 File which provides full model details, but brief details are given here.
Modelling of adherence and its effect on viral load and drug resistance
outcomes
We refer to adherence specifically as the average adherence in people on antiretroviral drugs.
Since our model updates in 3 month periods, short term interruptions of days or a few weeks
are treated as sub-optimal average adherence during the 3 month period. Interruption of ART
over periods of 3 months or greater are referred to as ART discontinuation and modelled
explicitly. ART discontinuation is usually concomitant with disengagement from clinic
attendance.
Average adherence in each 3 month period for an individual is determined from the under-
lying tendency to adhere (which is a lifelong value for the individual, unless changed as a result
of an adherence intervention) with within-person period-to-period variability (Fig 1) [6, 15–
24]. Each patient thus has a certain higher or lower tendency to adhere but their actual adher-
ence varies over time, both at random and according to the presence of symptoms (with drug
toxicity or presence of WHO stage 4 disease leading to a decrease in adherence) and age (ten-
dency for increasing adherence with age).
The average adherence in each 3 month period is a value between 0%-100%. Effects of
adherence on viral load and resistance acquisition risk are modelled by classifying levels
into < 50%, 50–79%, 80%, with effects of ART on viral load suppression being greater the
higher the adherence level and the resistance acquisition risk being highest in the 50%-79%
category. We do not distinguish between patterns of adherence at a level more granular than
the 3 monthly average level and hence cannot explicitly take into account the specific pattern
within the 3 month period, which could be important (e.g. whether 80% adherence consists of
missing drug one day in every five or a 1 week interruption in every 5 weeks). Thus the adher-
ence level in each period should be conceived of as conveying the degree to which the pattern
of adherence means that drug levels are maintained at intended therapeutic levels, rather than
simply the average adherence over the period.
This distribution of adherence levels is primarily determined by the adherence levels
required for the model outputs to mimic observed data. This includes data on rates of resis-
tance development and virologic failure and also data on the proportion of patients at first
virologic failure who have no resistance mutations present [25–37]. It is clear from such data
in more recent years that the great majority of patients who started ART with 3 or more drugs
are sufficiently adherent that virologic failure rates are low (and so resistance accumulation is
also likely to be low) [17, 38].
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The distribution of adherence over the first year of ART has been compared with data from
a large programme in Zambia (see Fig K in S1 File; [39]). The degree to which outputs on viral
load at one year from start of ART correspond to observed data is shown in Fig L in S1 File.
These are reconstructed outcomes for all people who have initiated ART in Zimbabwe up to
2014 (the overall mean CD4 count at initiation is 145 /mm3). Figs M and N in S1 File compare
Kaplan Meier estimates of time to virologic failure and resistance, respectively, between the
model and observed data, in the latter case data are from the UK due to the lack of data from
sub-Saharan Africa. Fig O in S1 File illustrates the proportion of people with resistance
(amongst those on ART with non-suppressed viral load) and corresponds to estimates from
the large WHO resistance surveillance.
Discontinuation of ART
Within the model, people can simultaneously discontinue ART and disengage from care (i.e.
they do not attend the clinic anymore) or can discontinue ART but still attend clinical visits.
The basic rate of discontinuation (for reasons apart from drug stock-out) is assumed to be 0.02
per 3 months; this rate is doubled in people with current toxicity (note that in addition to this
increased risk of discontinuation with current toxicity, there is assumed to be some substitu-
tion of drugs causing toxicity with available alternatives and a greater rate of discontinuation
in patients with a greater tendency to be non-adherent (1.5-fold if the person’s adherence aver-
age is 50–79% and 2-fold if their adherence average is < 50%) [40]. In a systematic review,
drug toxicity, adverse events and side effects have been found to be the most commonly given
reasons for drug discontinuation [40].
Fig 1. Modelling of distribution of adherence patterns over individuals in the population.
doi:10.1371/journal.pone.0167654.g001
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The rate of discontinuation also reduces with time on ART, decreasing after 1 year [41–43].
If the person’s average adherence is > 80% then there is a 30% chance that discontinuation
coincides with stopping visits to the clinic, if the long term average adherence is 50%-80% then
there is a 45% chance, and if the long term average adherence is< 50% then there is a 60%
chance. This is due to an assumption that factors leading to poor adherence are also likely to
be associated with disengagement from care. The rate of discontinuation and disengagement
from care is likely to vary by setting. Fig P in S1 File shows a comparison between modelled
and observed (from a study by Kranzer et al. [42] of Kaplan Meier estimates of the percent of
people having discontinued ART by time from ART initiation. Discontinuation of ART leads
to return of viral load to the pre-ART maximum and a relatively rapid CD4 return of CD4
towards pre-ART value [44].
Setting and intervention targeting and effect
We assume the adherence monitoring intervention is introduced in 2017 in the example set-
ting of Zimbabwe. The effect of any given adherence intervention (Table 1) is modelled as
effects on one or more of the following three elements: (i) enhanced average adherence when
on ART—implemented as a change in adherence to 95% for individuals in whom interven-
tion is currently effective; (ii) reduced risk of ART discontinuation—implemented as a 75%
reduction in risk of discontinuation for individuals in whom intervention is currently effec-
tive; (iii) reduced risk of resistance acquisition—implemented as a 50% lower risk of resistance
for individuals in whom intervention is currently effective. In each case this represents a
large effect at the individual level—the overall effect of the intervention is then determined
by the percent of people in whom the intervention is effective. We consider scenarios in
Table 1. Modelled intervention effects in individuals in whom adherence monitoring intervention is currently effective. In each case, this represents
a large effect at the individual level—the overall effect of the intervention is then determined by the percent of people in whom the intervention is effective.
Parameter potentially influenced by
adherence intervention
Value for parameter in absence of intervention Intervention effect
Distribution of average adherence when on
ART (each person’s underling tendency to
adhere) * and see Fig 1.
• 5% of the population have long term average
adherence 10%, period-to-period variability
(standard deviation = 20%)
• 10% of the population have long term average
adherence 80%, period-to-period variability
(standard deviation = 20%)
• 65% of the population have long term average
adherence 90%, period-to-period variability
(standard deviation = 5%)
• 20% of the population have long term average
adherence 95%, period-to-period variability
(standard deviation = 5%)
Change in adherence to 95% for individuals in
whom intervention is currently effective.
Risk of ART discontinuation Rate of 0.02 per 3 months (with higher rate in those
with ART toxicity and those with lower underlying
tendency to adhere)
75% decline in rate of risk of discontinuation (to
0.005) per 3 months for individuals in whom
intervention is currently effective.
Risk of resistance acquisition Dependent on current adherence, current number
of active drugs, current viral load (Details in
appendix)
50% lower risk of resistance for individuals in whom
intervention is currently effective.
* adherence in each 3 month period is determined by the person’s underlying tendency to adhere (which is a lifelong value, unless changed as a result of an
adherence intervention) with within-person period-to-period variability. The within person variability is also a lifelong value. Adherence is also influenced by
(i) current toxicity (current ADC) (ii) start second line (iii) viral load measurement > 1000 copies/mL. This distribution of adherence patterns is chosen on the
basis of data on adherence and on patterns on virologic failure in people followed on ART. Details in S1 File.
doi:10.1371/journal.pone.0167654.t001
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which the adherence intervention is effective in 20%, 50% or 80% of people to whom it is
applied. We consider that the intervention has potential effects for all people on ART, includ-
ing those who have high average adherence (e.g. by potentially reducing the risk of discontin-
uation). The intervention effect is considered to be durable for up to the full 20 year time
horizon that we consider, although a shorter duration of effect (1 year) is considered in sensi-
tivity analyses.
ART monitoring strategy
We consider two main scenarios regarding laboratory monitoring of people on ART. One in
which the roll-out of viral load testing will occur as planned in Zimbabwe by 2017, the other
in which viral load testing is not available and hence the CD4 count is still used (using a
switching strategy based on absolute CD4 count) [11]. In the scenario in which we assume
that viral load monitoring is in place we consider also the effects of viral load measurement
triggering a positive effect on adherence. Viral load being identified as being above 1000 cop-
ies/mL is assumed to lead to an increase in adherence in 70% of people as a result of targeted
adherence intervention; this is consistent with data showing that a high proportion of people
with measured viral load > 1000 copies/mL who undergo an adherence intervention subse-
quently achieve viral suppression without a change in ART [45–48] and broadly consistent
with a meta-analysis [49]. Although the appropriate duration to assume for this effect is
uncertain [47] we assume, consistent with our previous work [11], that the adherence inter-
vention is effective only the first time the viral load triggers an adherence intervention and
that for 40% the effect is permanent (i.e. 70% x 40% = 28% of those with a viral load >1000),
but that in the remaining 60% (i.e. 70% x 60% = 42% of those with viral load>1000) it lasts
only 6 months.
Differentiation of care
In the scenario in which viral load monitoring is not available (as remains the case in many
low income settings in sub-Saharan Africa) we consider that the adherence monitoring-
based intervention can be used to differentiate care. In particular, for those with high adher-
ence over the past 3 month period, visits are simplified such that visit costs are reduced by
50% (from $20 per 3 months to $10), based on the concept that adherence can be rapidly
checked and, if high and no symptoms present, then a pharmacy-only visit is possible. In
terms of health outcomes, being on such a simplified visit schedule is assumed to have the
effect that if a WHO stage 4 condition develops then the risk of death due to the condition is
1.5 times raised, as result of potentially later detection of symptoms by clinic staff. If viral
load monitoring is used, then we assume that care can also be differentiated, primarily
according to the most recent viral load measured in the past year, with again a 50% reduc-
tion in visit costs if the most recent viral load is < 1000 copies/mL and this has been mea-
sured in the past year. However, if the adherence monitoring-based intervention is in use
and no viral load measure is available in the past 1 year but if the most recent viral load
was < 1000 copies/mL and the adherence measure shows > 80% adherence then we again
assume that visit costs are also reduced in this circumstance. This use of the objective adher-
ence monitoring to identify additional opportunities for reduced clinic visits includes the
second 3 month period after start of ART (because the first viral load test is at 6 months). In
a key additional analysis we also consider the possibility that even when viral load monitor-
ing is available the viral load testing will cease in those in whom viral load suppression has
been demonstrated where there is an adherence monitoring based intervention in place and
adherence is > 80%.
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Economic considerations
Programme costs resulting from adherence monitoring interventions are also considered to
allow a full economic evaluation. The cost of the intervention is considered per person year on
ART. Our objective is to maximize population health from within available health care
resources. A health sector perspective has therefore been adopted for the analysis, so direct
and indirect costs incurred by the patients are not included. Health benefits associated with
the adherence intervention are estimated using the metric DALYs averted in the entire adult
population. The increment in programme costs resulting from introduction of the adherence
monitoring intervention divided by number of DALYs averted (the health benefit) gives the
incremental cost effectiveness ratio (ICER). The ICER can be compared with a cost effective-
ness threshold to ascertain whether the intervention is likely to represent an appropriate use of
resources given the opportunity costs of using those resources for this purpose (i.e. to be cost
effective). The cost-effectiveness threshold for a country represents the opportunity costs of
resources required to fund the intervention, in terms of the health gains those resources could
generate if used for alternative purposes in the public health care system [50]. As such, the
threshold for a country is not readily apparent, but $500 per DALY averted is likely to be at the
upper end based on the magnitude of benefit if resources were spent on other programmatic
priorities [51]. We consider the cost that the intervention would have to be delivered at in
order for it to be cost effective based on the $500 threshold. We consider a 20 year time per-
spective from 2017–2036. Both costs and health benefits were discounted to present value
using a 3% per annum discount rate in our base case. The modelling results are intended to
inform decisions in sub-Saharan African countries classified as low and low-middle income
countries using the World Bank country classification.
Disability weights to calculate DALYs averted were derived from a recent comprehensive
study [52]. Unit costs (in $US at 2014 prices) are detailed in S1 File. In brief, costs of viral load
assays are assumed to be $22, counting all components of the cost (reagents, costs of equip-
ment, human resources, buildings, etc.) (details in S1 File [53, 54]). Likewise, the cost of mea-
suring CD4 counts is assumed to be $10 [55]. The current annual cost (including supply
chain) of the first-line regimen of efavirenz, emtricitabine, tenofovir (assumed used as a fixed
dose combination) is assumed to be $144 per person per year and second-line regimen of zido-
vudine, emtricitabine, ritonavir-boosted atazanavir $312 per person per year [56]. Programme
costs for clinic visits (not including drug or viral load / CD4 count tests) are $20 per 3 months
[57, 58] with an assumed reduction to $10 per 3 months when care is differentiated and the
person has viral suppression or high measured adherence.
Sensitivity analyses
Besides considering the various possible component effects of the adherence monitoring
intervention, and varying the percent of people in whom the intervention has an effect, we
considered the effect of varying several other factors. We considered scenarios in which: the
overall population adherence profile was lower or higher; the background rate of treatment
discontinuation was lower or higher; the intervention effect was of 1 year duration only;
there was no differentiation of care based on adherence; there is no effect of viral
load > 1000 on adherence; there was no differentiated care (neither driven by viral load nor
by adherence); there is only a $5 per 3 month saving from adherence-informed differentiated
care; and where the adherence intervention is used instead of viral load monitoring. Finally,
we consider a sensitivity analysis in which we change the underlying adherence structure
such that a person’s underlying tendency to adhere can shift during their lifetime for other
reasons besides the adherence interventions, for example due to changes in life
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circumstances (their “lifetime” adherence is re-sampled from the original distribution used
to generate each individuals lifetime adherence level). We operationlise this as a 2% chance
per 3 month period that a person’s underlying tendency to adhere is changed, to a value
based on a re-sampling from the distribution in Fig 1.
Results
The status of the simulated adult population of Zimbabwe in 2014 is shown in Table A in S1
File. Outputs from the model include: number of adults living with HIV 1,161,000 out of a
population size of 8,117,000 aged 15–65; prevalence of HIV in women age 15–45 17%; 2.8 mil-
lion HIV tests done in the year; 655,000 people on ART, meaning that 56% of all people with
HIV were on ART; death rate for people on ART 3.21 /100 person years, for all HIV positive
people 5.22 /100 person years; of people on ART the proportion with viral load< 500 copies/
mL 82%. By 2016, the model has 776,000 on ART (66% of all people with HIV).
The modelled outcomes of the introduction of an adherence monitoring intervention in
2017, according to the attributes of that intervention, are shown in Table 2. Outcomes shown
are averages over 20 years from 2017–2036. As our main overall measure of the effect of the
adherence monitoring-based interventions we consider the population of ART experienced
people (i.e. i.e. all those who have ever started ART regardless of whether they remain on
ART) and focus on the proportion of this population with high adherence and the proportion
with viral load< 1000 copies / mL. The reason for considering this measure is that each of the
various components of the effect of the adherence monitoring-based intervention act to
increase this proportion. When considering our measure of population health, DALYs, we
consider the whole adult population, those with and HIV and those without. This is because
we wish to take into account the effects of the intervention on reduced HIV transmission. First
(Table 2a), viral load monitoring is assumed not to be in place during the 20 year period
(which is not likely to be the case in Zimbabwe itself but could be elsewhere in the region). If
the intervention is effective in only 20% of the population then the effect on the proportion of
ART experienced people with viral load suppression below 1000 copies/mL is only 2.7%, even
when all three components of the effect are present: improving adherence in those on ART,
reducing the rate of discontinuation of those on ART, and reducing the risk of resistance
acquisition. This modest effect is largely due to the relatively high levels of adherence without
the intervention. Even so, an intervention with this effect costing $37 per person on ART per
year (including patients in whom the intervention is not effective) would be cost effective, due
mainly to the clinic visit savings from differentiation of care. Considering that the intervention
is effective in 50% of people rather than 20% there is now a 6.5% benefit on the proportion of
ART experienced people with viral load suppression below 1000 copies/mL with the adherence
intervention if it has an effect on all three components listed above. Of the three components,
it is the effect on reducing the rate of ART discontinuation that had the greatest beneficial
effects. The death rate in those with diagnosed HIV is likewise reduced, from 4.69 per 100 per-
son years with no intervention to 4.08 per 100 person years (i.e. a 13% relative reduction) with
an intervention having an effect on all three components. When the intervention has an effect
on 80% of people then with an effect on all three components there is an 8.2% benefit in terms
of proportion of ART experienced people with viral load suppression and a 20% reduction in
death rate in people with diagnosed HIV from 4.69 to 3.73 / 100 person years. In this situation,
an intervention with this effect costing $62 per person on ART per year would be cost effective.
The maximum intervention cost to be cost-effective is lowest when the intervention only influ-
ences ART discontinuation (combination of components (c), second column in Table 2). This
is due to the fact that more drug costs are incurred, whereas when there are beneficial effects
Cost Effectiveness of Potential ART Adherence Monitoring Interventions in Sub-Saharan Africa
PLOS ONE | DOI:10.1371/journal.pone.0167654 December 15, 2016 8 / 20
on average adherence or on resistance acquisition while on ART there are no additional drug
costs assumed.
Fig 2a shows the breakdown in costs. This is based on a notional intervention cost per year
per person on ART (i.e. those adherent as well as those not adherent) of $10. The effect of the
Table 2. Outcomes of adherence interventions according to the components the intervention has an effect on, the percent of people the interven-
tion is effective in and whether viral load monitoring is employed, all in the context of an intervention with a durable effect.
% of people
adherence
intervention
effective in
Components intervention
has beneficial effect on (a)
adherence on ART only (b)
adherence on ART
+ discontinuation of ART (c)
discontinuation of ART only
(d) adherence on ART + risk
of resistance (e) adherence
on ART + discontinuation of
ART + risk of resistance
Proportion of
ART experienced
people on ART
with high
adherence
Proportion of
ART experienced
people with viral
load < 1000
Death rate in
ART
experienced
people
DALYs averted per
3 months (over 20
years, compared
with no
intervention)
Maximum cost of
adherence
intervention (per
person on ART per
year) to be cost
effective
(a) No viral load monitoring
No intervention - - - 0.805 0.741 4.69 - - - - - -
20 (a) 0.812 0.747 4.62 1226 $33
20 (b) 0.828 0.760 4.48 2889 $35
20 (c) 0.818 0.752 4.55 2203 $30
20 (d) 0.812 0.753 4.59 1534 $34
20 (e) 0.828 0.768 4.44 3483 $37
50 (a) 0.823 0.756 4.54 2425 $38
50 (b) 0.861 0.788 4.16 7409 $46
50 (c) 0.838 0.770 4.34 4822 $34
50 (d) 0.823 0.771 4.43 3562 $42
50 (e) 0.862 0.806 4.08 8282 $50
80 (a) 0.833 0.764 4.42 3868 $44
80 (b) 0.892 0.813 3.87 11836 $53
80 (c) 0.856 0.784 4.14 7445 $36
80 (d) 0.834 0.788 4.27 5901 $53
80 (e) 0.893 0.843 3.73 13017 $62
(b) Viral load monitoring
No intervention - - - 0.817 0.766 4.61 - - -
20 (a) 0.823 0.772 4.56 1281 $8
20 (b) 0.838 0.784 4.42 2457 $8
20 (c) 0.830 0.778 4.48 2416 $7
20 (d) 0.823 0.775 4.53 1087 $7
20 (e) 0.839 0.790 4.37 3407 $12
50 (a) 0.831 0.778 4.47 2118 $11
50 (b) 0.867 0.811 4.13 6573 $17
50 (c) 0.848 0.795 4.26 4489 $8
50 (d) 0.832 0.791 4.40 2989 $17
50 (e) 0.868 0.825 4.04 7833 $23
80 (a) 0.840 0.785 4.41 3232 $17
80 (b) 0.895 0.835 3.83 11209 $28
80 (c) 0.867 0.811 4.03 7647 $12
80 (d) 0.840 0.805 4.25 5074 $26
80 (e) 0.896 0.859 3.70 12444 $36
doi:10.1371/journal.pone.0167654.t002
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adherence monitoring based intervention in reducing costs can be seen. The component of
the intervention that generally has the greatest beneficial effect on averting DALYs is to reduce
the rate of discontinuation. This however involves greater use of ART and so tends to also
increase costs. Improvements in ART adherence or risk of resistance in those already on ART
has a more modest beneficial effect than an effect in reducing ART discontinuation but does
not incur additional costs apart from the cost of the intervention and in fact leads to less use of
second line ART which acts to relieve cost burden somewhat.
In sensitivity analyses (Table 3a), in which we consider that the intervention is effective in
50% of people, the intervention cost per person on ART per year required for it to be cost
effective was in the $29-$58 range, except in the situation where we assume that care is not dif-
ferentiated and thus there are no savings in visit costs ($5-$20 cost in order to be cost effective).
Since the cost effectiveness is mainly dependent on the ability of adherence monitoring to dif-
ferentiate care, the intervention is cost effective in the range $30-$35 per person on ART per
year even where the effect of the intervention in improving adherence lasts only 1 year.
When viral load monitoring is available (Table 2b), benefits in terms of viral suppression,
death rates and DALYs are similar to the case without viral load monitoring. However, since
Fig 2. Overall programme costs according to components intervention has beneficial effect on ((a) adherence on ART only (b)
adherence on ART + discontinuation of ART (c) discontinuation of ART only (d) adherence on ART + risk of resistance (e)
adherence on ART + discontinuation of ART + risk of resistance). Costs in US$m per 3 months (mean 2017–2036, discounted at
3% per annum from 2015). For scenario with 50% of people in whom the intervention has an effect, and a durable effect. For illustrative
purposes, the adherence intervention has an arbitrarily selected cost of $10 per year per person on ART.
doi:10.1371/journal.pone.0167654.g002
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Table 3. Sensitivity analyses (a) in context of no viral load monitoring (b) in context of viral load monitoring. All in context of an intervention with a
durable effect and the intervention being effective in 50% of people.
(a) no viral load monitoring
Sensitivity analysis Components
intervention has
beneficial effect on
Proportion of ART
experienced people
with viral load < 1000
Death rate in ART
experienced
people
DALYs averted per 3
months (over 20 years,
compared with no
intervention)
Maximum cost of
adherence intervention (per
person on ART per year) to
be cost effective
Base case No intervention 0.741 4.69 - - -
(a) 0.756 4.54 2425 $38
(b) 0.788 4.16 7409 $46
(c) 0.770 4.34 4822 $34
(d) 0.771 4.43 3562 $42
(e) 0.806 4.08 8282 $50
Lower adherence No intervention 0.651 5.85 .
(a) 0.699 5.20 9977 $64
(b) 0.733 4.76 15105 $68
(c) 0.673 5.46 4779 $28
(d) 0.714 5.11 10601 $69
(e) 0.753 4.67 16382 $76
Higher adherence No intervention 0.768 4.40 .
(a) 0.772 4.35 101 $29
(b) 0.802 4.00 5246 $37
(c) 0.796 4.07 4035 $33
(d) 0.788 4.24 2125 $38
(e) 0.821 3.91 6696 $45
Lower rate of ART
discontinuation
No intervention 0.778 4.21 .
(a) 0.795 4.05 2654 $39
(b) 0.812 3.86 5400 $42
(c) 0.792 4.04 2135 $29
(d) 0.812 3.94 3378 $42
(e) 0.83 3.77 6324 $48
Higher rate of ART
discontinuation
No intervention 0.672 5.65 .
(a) 0.683 5.47 2328 $36
(b) 0.744 4.73 11744 $50
(c) 0.725 4.92 9384 $39
(d) 0.696 5.37 3688 $43
(e) 0.761 4.64 13117 $58
Duration of effect 1 year only No intervention 0.741 4.69 .
(a) 0.744 4.66 802 $31
(b) 0.746 4.61 2026 $34
(c) 0.744 4.65 1125 $30
(d) 0.747 4.63 1172 $33
(e) 0.750 4.59 2328 $35
No adherence-informed
differentiated care
No intervention 0.741 4.70 .
(a) 0.755 4.53 2205 $8
(b) 0.787 4.15 7414 $15
(c) 0.768 4.34 4812 $5
(d) 0.771 4.43 3228 $12
(e) 0.806 4.06 8417 $20
(Continued )
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Table 3. (Continued)
Alternative underlying
adherence pattern
No intervention 0.719 4.87 .
(a) 0.743 4.62 3467 $40
(b) 0.776 4.25 7815 $45
(c) 0.745 4.51 4608 $31
(d) 0.759 4.55 4017 $45
(e) 0.795 4.15 9448 $54
(b) viral load monitoring
Sensitivity analysis Components
intervention has
beneficial effect on
Proportion of ART
experienced people
with viral load < 1000
Death rate in ART
experienced
people
DALYs averted over 20
years (compared with no
intervention)
Maximum cost of
adherence intervention (per
person on ART per year) to
be cost effective
Base case No intervention 0.766 4.61 - - -
(a) 0.778 4.47 2118 $11
(b) 0.811 4.13 6573 $17
(c) 0.795 4.26 4489 $8
(d) 0.791 4.40 2989 $17
(e) 0.825 4.04 7833 $23
Viral load testing stopped for
people with viral load < 1000
if adherence > 80%
No intervention 0.766 4.61 .
(a) 0.772 4.56 1381 $19
(b) 0.805 4.21 6242 $27
(c) 0.789 4.34 3963 $16
(d) 0.786 4.44 2360 $25
(e) 0.821 4.09 7303 $32
Lower adherence No intervention 0.689 5.51 .
(a) 0.729 5.04 7296 $35
(b) 0.765 4.62 12411 $39
(c) 0.713 5.13 4913 $7
(d) 0.743 4.97 8701 $42
(e) 0.780 4.54 13849 $47
Higher adherence No intervention 0.789 4.36 .
(a) 0.793 4.32 1099 $6
(b) 0.823 3.99 4989 $12
(c) 0.819 4.04 3702 $6
(d) 0.805 4.23 1787 $11
(e) 0.838 3.90 6721 $20
Lower rate of ART
discontinuation
No intervention 0.806 4.12 .
(a) 0.819 4.00 2173 $11
(b) 0.837 3.81 4073 $12
(c) 0.820 3.97 2049 $3
(d) 0.834 3.92 2778 $16
(e) 0.852 3.74 5265 $19
Higher rate of ART
discontinuation
No intervention 0.694 5.56 .
(a) 0.703 5.44 1470 $9
(b) 0.764 4.70 10577 $23
(c) 0.748 4.87 8692 $15
(d) 0.714 5.33 2838 $16
(e) 0.778 4.62 11739 $31
(Continued )
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there is less of a benefit in cost due to the fact that care is already differentiated, based on viral
load (Fig 2), the cost of the adherence monitoring-based intervention required to be cost effec-
tive is substantially lower. Still, an intervention costing $23 per year per person on ART, if it
increases the proportion of ART experienced people with viral load< 1000 cps/mL by 5.9%,
would be cost effective.
If viral load monitoring is available as well as an adherence monitoring intervention then
perhaps a more likely situation than our base case is that viral load measurement will be ceased
in people with a previous viral load level measured below 1000 copies/mL and > 80% adher-
ence since the viral load measurement. In this case (Table 3b), an intervention costing $32 per
Table 3. (Continued)
Duration of effect 1 year only No intervention 0.766 4.61 - - -
(a) 0.768 4.59 572 $5
(b) 0.769 4.55 1853 $8
(c) 0.767 4.58 1111 $5
(d) 0.770 4.56 1175 $7
(e) 0.771 4.51 2146 $9
No adherence-informed
differentiated care
No intervention 0.766 4.60 .
(a) 0.777 4.48 1804 $8
(b) 0.81 4.13 6618 $18
(c) 0.795 4.25 4744 $7
(d) 0.791 4.38 2818 $13
(e) 0.825 4.02 7683 $21
No effect of viral load > 1000
on adherence
No intervention 0.759 4.69 .
(a) 0.772 4.53 2422 $13
(b) 0.807 4.16 7078 $18
(c) 0.79 4.33 4806 $9
(d) 0.785 4.44 3419 $18
(e) 0.822 4.08 8519 $26
No differentiated care (neither
driven by viral load nor by
adherence)
No intervention 0.765 4.61 .
(a) 0.777 4.47 1794 $7
(b) 0.811 4.10 6561 $12
(c) 0.795 4.24 4410 $4
(d) 0.79 4.38 2532 $11
(e) 0.825 4.03 7694 $19
Adherence intervention
instead of viral load
monitoring **
No intervention 0.766 4.60 .
(a) 0.756 4.54 930 $10
(b) 0.788 4.17 5760 $18
(c) 0.768 4.34 3224 $5
(d) 0.771 4.43 2018 $16
(e) 0.806 4.07 6869 $23
Alternative underlying
adherence pattern
No intervention 0.747 4.75 .
(a) 0.767 4.56 2775 $15
(b) 0.801 4.19 7777 $23
(c) 0.775 4.39 4410 $6
(d) 0.78 4.49 3397 $20
(e) 0.816 4.12 8480 $28
** here only the no intervention scenario has viral load monitoring.
doi:10.1371/journal.pone.0167654.t003
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year per person on ART, if it increases the proportion of ART experienced people with viral
load< 1000 cps/mL by 5.5%, would be cost effective.
In sensitivity analyses (Table 3b), the maximum intervention cost permissible for it to be
cost effective is also higher in the situations where the adherence levels in the population are
generally lower or when the intervention replaces viral load monitoring rather than being in
addition.
Discussion
In this paper we use a mathematical model which captures the joint effects of adherence and
viral resistance on response to ART in order to provide a link between viral suppression out-
comes of a putative adherence monitoring intervention and key programme outcomes of
death rates and DALYs. This should facilitate use of data from trials of adherence monitoring
interventions to be used to predict the population impact of the interventions, and hence allow
assessment of cost effectiveness of such interventions. Our results should also be useful in the
design of trials when specifying the target effect for viral load or adherence outcomes, for sam-
ple size calculation.
In assessing cost effectiveness of adherence monitoring-based interventions it is important
to consider what laboratory monitoring is in place, if any. We considered our adherence moni-
toring intervention in three main contexts: one in the presence of viral load monitoring where
viral load monitoring continues alongside the adherence monitoring intervention, one in
which viral load monitoring is available but is selectively replaced by adherence monitoring,
and one in the complete absence of viral load monitoring. Given that the non-ART pro-
gramme costs of providing for clinic visits average $60-$90 per year in low income settings in
Africa, approaches that enable differentiation of care to allow less clinical visits in those doing
well on ART are potentially highly significant [58]. We assumed that in the scenario where
viral load monitoring is available such an approach is employed. However, although viral load
monitoring is recommended in WHO guidelines, the roll out in many countries in Africa
towards that goal has been modest, largely due to the complexities of setting up and continu-
ally running central laboratories with the capacity to meet demand for measurement of viral
load on dried blood spot or plasma samples, and the current lack of a suitable affordable point
of care assay [53]. For this reason we also considered a scenario in which viral load monitoring
is not available, and here we assumed a CD4 count monitoring strategy is used, without differ-
entiation of care (in the absence of an adherence-monitoring intervention).
Adherence monitoring-based interventions also could potentially be used to enable differ-
entiation of care so that those with high adherence can have reduced visit frequency, reduced
VL monitoring and/or attend for pharmacy-only visits. This represents a significant potential
benefit, alongside the beneficial effect of improvements in adherence/retention in those with
sub-optimal adherence. In settings without viral load monitoring available, the potential for
adherence monitoring based interventions to represent a cost-effective approach is substantial.
Our results suggest that adherence monitoring-based interventions can cost as much as
approximately $62 per person on ART per year and represent a cost effective approach. This is
an average cost over all people on ART, including those who are adherent without any inter-
vention. Considering that costs for the approximately 80% of people with high adherence
might be no more than $5 per year, this leaves $290 per year each for the approximately 20%
of people who have suboptimal or poor adherence. Even where viral load monitoring is avail-
able there is a potentially important role for adherence monitoring-based interventions. We
assumed in our base case that care would be differentiated according to the adherence level,
measured by adherence monitoring, whenever the most recent viral measure was < 1000 cps/
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mL but more than one year in the past. With an adherence monitoring based intervention
leading to a 5% increase in the proportion of ART experienced people with viral
suppression < 1000 copies/mL (Table 2) the intervention is cost effective if costing $23 per
year person on ART or less ($95 per year for each of the 20% with poor adherence). An alter-
native, and perhaps more likely, approach could be to stop viral load monitoring in those with
high levels of adherence and continue on a reduced visit frequency unless the adherence level
declines, at which point viral load monitoring can be resumed until viral load suppression and
high adherence are achieved. With this approach the adherence intervention can be as high as
$32 per person on ART per year and remain cost effective. Further studies to compare health
outcomes from different approaches to use adherence monitoring in tandem with viral load
testing in a cost efficient way would be helpful. We assume a modest effect of viral load being
measured above 1000 copies/mL on adherence, but this was not very influential in our results
and the maximum cost for the intervention to be cost effective was similar in sensitivity analy-
ses when this assumed beneficial effect on adherence was removed.
The relationship between the proportion of ART experienced people virally suppressed and
mortality in ART experienced people will depend on various characteristics of the HIV posi-
tive population, particularly the CD4 count profile and the CD4 count nadir (the level to
which the CD4 will tend to fall over the first few months of ART discontinuation, should this
occur). Our findings are most specifically relevant to Zimbabwe, but given that we have con-
sidered a range of scenarios in terms of existing ART monitoring strategy (viral load monitor-
ing or not), population adherence profile, and population tendency to discontinue ART, our
findings regarding the translation of intervention effectiveness into DALYs averted should be
reasonably generalizable across sub-Saharan Africa. Regarding costs, we provide a breakdown
of cost components so that country-specific costs for other countries could be utilized if
required. We use a cost-effectiveness threshold of $500 to reflect the value (opportunity costs)
of other claims on resources, but this value is uncertain and may well be different in other
countries. A lower threshold will mean that intervention costs need to be lower in order to be
cost-effective.
Examples of objective adherence-monitoring based interventions are use of pharmacy and
drug pick up records and use of electronic adherence monitors, including real time monitors
using mobile-phone technology. Neither is a perfect measure but both are likely to be more
accurate than subjective measures such as self report. Perhaps the most relevant objective mea-
sure of adherence is the plasma drug level but it is currently hard to conceive that this latter
measure could be used in routine care.
To our knowledge there is little similar work to ours which has been conducted. Kessler
and colleagues considered the impact and cost-effectiveness of hypothetical strategies to
enhance retention in care within HIV treatment programs in East Africa [59]. They concluded
that programs should consider retention-focused programs once they have already achieved
high degrees of ART coverage among eligible patients, and noted that it is important that deci-
sion makers understand the epidemiology and associated outcomes of those patients who are
classified as lost to follow up in their systems prior to implementation in order to achieve the
highest value. In addition, Petersen et al, have used marginal structural models to estimate the
effect of pillbox organisers on adherence and viral load outcomes and, in the United States
context, found them to be associated with cost per QALY of $19,000 [60]. Cost effectiveness of
adherence interventions has been reviewed [61], with the conclusion that they can be cost
effective, but those results are of limited relevance for sub-Saharan Africa.
Converting the efficacy, measured in terms of level of viral load suppression, into clinical
and mortality outcomes is not straightforward. This issue was initially raised when the Food
and Drug Administration was taking a decision on whether to licence drugs based on trials
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with viral load rather than clinical endpoints as outcomes [62–64]. Analyses of trials in which
viral load was assessed as well as clinical outcomes were used.
There are limitations of this work. The model updates in 3 month periods and therefore it
is not suited to capture specific patterns of adherence. Because average adherence is a relatively
insensitive predictor of VL failure compared to discontinuations, this is a conservative bias.
Electronic monitoring which incorporates discontinuations would add to the predictive
power, lead to better differentiation and improve cost effectiveness. Qualitative data by Ware
and quantitative data by Haberer suggests that the mere presence of electronic monitoring cre-
ates a perception of “connectedness to clinic” and may improve adherence by the presence of
monitoring alone, even without explicit intervention [65, 66]. Such a Hawthorne effect would
increase the cost-effectiveness of our estimates. Lastly, by the nature of any model we have not
captured all subtleties of real life and cannot rule out that some are important in affecting the
outcomes we modelled. Lastly, we used a 20 year time horizon and ideally we would have used
a longer time period to allow effects to play out over a longer period.
In conclusion, our results suggest that there is clear scope for adherence monitoring-based
interventions to provide net population health gain in low income settings in sub-Saharan
Africa, with potential cost-effective use in situations where viral load monitoring is or is not
available. Our results should guide the implementation of future adherence monitoring inter-
ventions found in randomized trials and other studies to have health benefit.
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